XenoGesis, a leading laboratory-based CRO, was founded in 2011, specialising in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, pharmacology and expert interpretation.
Based at BioCity in Nottingham, XenoGesis became part of Sygnature Discovery in September 2020, creating a team of over 60 DMPK scientists who, together with the multidisciplinary teams at Sygnature, now offer a truly integrated drug discovery service to customers across the globe.
Join us at our new home on sygnaturediscovery.com to find all of the services you are familiar with from XenoGesis, as well as our full suite of integrated drug discovery and non-clinical solutions.
Who are Sygnature Discovery?
Sygnature Discovery are a world-leading provider of integrated drug discovery and non-clinical solutions.
Our mission is simple: to add genuine value to our customers’ research projects through intellectual input, an ethos of true partnership, and a wealth of world-class drug discovery expertise. We offer target validation, hit identification, hit-to-lead, lead optimisation and fully integrated drug discovery programmes.
It’s important to us that our team can collaborate on an equal footing with our customers’ scientists to drive their drug discovery projects towards the clinic. With that principle we have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified).
Sygnature's capabilities include:
- medicinal chemistry
- in vitro biology
- computational chemistry and informatics
- DMPK
- protein crystallography (via affiliate company Peak Proteins)
- pre-clinical experimental services
Since 2011, 37 compounds discovered by Sygnature for customers have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).
The XenoGesis team can now be reached at Sygnature Discovery.
If you have an enquiry and would like to talk to a scientist please contact us.
Sites
Sygnature Discovery operates two integrated drug discovery sites at BioCity, Nottingham, and Alderley Park, Cheshire, in the UK, as well as an office presence in the biotech hub of Boston, MA, in the USA.
Sygnature Discovery Limited, BioCity,
Pennyfoot Street, Nottingham NG1 1GR,
United Kingdom